PHYHIPL

Across TCGA pan-cancer cohorts, PHYHIPL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHYHIPL data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PHYHIPL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PHYHIPL expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where PHYHIPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.860	0.664	<.001	70	view →
LUAD	OS	Median	II,III,IV	0.273	0.732	.003	26	view →
CCRCC	OS	Quartile	All	0.930	0.449	.010	17	view →
LSCC	DFS	Tertile	All	0.495	0.928	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PHYHIPL–PDAC (DFS)

Open the PDAC breakdown →